Published in Health Serv Res on January 31, 2008
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Challenges in building disease-based national health accounts. Med Care (2009) 1.50
Catastrophic household expenditure on health in Nepal: a cross-sectional survey. Bull World Health Organ (2014) 1.09
State-level projections of cancer-related medical care costs: 2010 to 2020. Am J Manag Care (2012) 1.06
The economic burden of vision loss and eye disorders among the United States population younger than 40 years. Ophthalmology (2013) 0.89
Costs of Chronic Diseases at the State Level: The Chronic Disease Cost Calculator. Prev Chronic Dis (2015) 0.83
State-level estimates of cancer-related absenteeism costs. J Occup Environ Med (2013) 0.79
State-level cancer treatment costs: how much and who pays? Cancer (2013) 0.79
Guidelines for Measuring Disease Episodes: An Analysis of the Effects on the Components of Expenditure Growth. Health Serv Res (2016) 0.75
Actual causes of death in the United States, 2000. JAMA (2004) 44.38
Excess deaths associated with underweight, overweight, and obesity. JAMA (2005) 22.17
Use and misuse of population attributable fractions. Am J Public Health (1998) 12.96
National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood) (2003) 6.11
Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ (2005) 4.52
Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ (1998) 3.97
State-level estimates of annual medical expenditures attributable to obesity. Obes Res (2004) 3.20
Why population attributable fractions can sum to more than one. Am J Prev Med (2004) 2.12
Sequential and average attributable fractions as aids in the selection of preventive strategies. J Clin Epidemiol (1995) 1.94
Cost-of-illness studies : a review of current methods. Pharmacoeconomics (2006) 1.84
A comparison of the case-control and case-crossover designs for estimating medical costs of nonfatal fall-related injuries among older Americans. Med Care (2005) 1.14
A robust approach for skewed and heavy-tailed outcomes in the analysis of health care expenditures. J Health Econ (2006) 1.11
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63
The economic burden of major adult visual disorders in the United States. Arch Ophthalmol (2006) 2.92
The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology (2009) 2.57
A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manag Sci (2003) 2.47
Environment, obesity, and cardiovascular disease risk in low-income women. Am J Prev Med (2006) 2.39
Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring) (2008) 2.23
Cost effectiveness of internet interventions: review and recommendations. Ann Behav Med (2009) 2.21
Medical costs and productivity losses due to interpersonal and self-directed violence in the United States. Am J Prev Med (2007) 2.15
Cancer treatment cost in the United States: has the burden shifted over time? Cancer (2010) 2.10
Effect of a stepped-care intervention approach on weight loss in adults: a randomized clinical trial. JAMA (2012) 2.02
Public perceptions of childhood obesity. Am J Prev Med (2005) 1.85
Individual and aggregate years-of-life-lost associated with overweight and obesity. Obesity (Silver Spring) (2009) 1.62
Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making (2006) 1.58
Considerations for an obesity policy research agenda. Am J Prev Med (2009) 1.57
An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care (2006) 1.51
State-level Medicaid expenditures attributable to smoking. Prev Chronic Dis (2009) 1.50
The cost-effectiveness of Welcome to Medicare visual acuity screening and a possible alternative welcome to medicare eye evaluation among persons without diagnosed diabetes mellitus. Arch Ophthalmol (2012) 1.49
The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract (2007) 1.49
Return on investment for bariatric surgery. Am J Manag Care (2008) 1.48
State- and payer-specific estimates of annual medical expenditures attributable to obesity. Obesity (Silver Spring) (2011) 1.47
Medical costs of CKD in the Medicare population. J Am Soc Nephrol (2013) 1.45
Health economics in public health. Am J Prev Med (2009) 1.44
A nationwide community-based lifestyle program could delay or prevent type 2 diabetes cases and save $5.7 billion in 25 years. Health Aff (Millwood) (2012) 1.44
High-risk individuals' willingness to pay for diabetes risk-reduction programs. Diabetes Care (2006) 1.41
Youth BMI trajectories: evidence from the NLSY97. Obesity (Silver Spring) (2009) 1.36
Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med (2013) 1.34
Cost-effectiveness of diabetes self-management programs in community primary care settings. Diabetes Educ (2009) 1.26
Estimates of state-level health-care expenditures associated with disability. Public Health Rep (2010) 1.25
Beyond effectiveness: evaluating the public health impact of the WISEWOMAN program. Am J Public Health (2007) 1.17
Health promotion interventions for disadvantaged women: overview of the WISEWOMAN projects. J Womens Health (Larchmt) (2004) 1.16
Young adult weight trajectories through midlife by body mass category. Obesity (Silver Spring) (2013) 1.15
Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics (2007) 1.13
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer (2011) 1.10
Comparing cost-of-illness estimates from alternative approaches: an application to diabetes. Health Serv Res (2009) 1.08
Insurance coverage and incentives for weight loss among adults with metabolic syndrome. Obesity (Silver Spring) (2008) 1.02
Methods for estimating medical expenditures attributable to intimate partner violence. J Interpers Violence (2008) 1.00
Spatial analysis of body mass index and smoking behavior among WISEWOMAN participants. J Womens Health (Larchmt) (2004) 1.00
Cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmology (2007) 0.98
Optimizing linkage and retention to hypertension care in rural Kenya (LARK hypertension study): study protocol for a randomized controlled trial. Trials (2014) 0.96
A cluster randomised controlled trial evaluating an incentive-based outdoor physical activity programme to increase outdoor time and prevent myopia in children. Ophthalmic Physiol Opt (2014) 0.94
Estimating older adults' preferences for walking programs via conjoint analysis. Am J Prev Med (2009) 0.94
A return-on-investment simulation model of workplace obesity interventions. J Occup Environ Med (2009) 0.91
The economic burden of vision loss and eye disorders among the United States population younger than 40 years. Ophthalmology (2013) 0.89
Alternative HbA1c cutoffs to identify high-risk adults for diabetes prevention: a cost-effectiveness perspective. Am J Prev Med (2012) 0.86
The impact of medication use in a multicomponent intervention: results from the WISEWOMAN program. Am J Health Promot (2007) 0.84
Cost-effectiveness analysis of the national Perinatal Hepatitis B Prevention Program. Pediatrics (2014) 0.84
Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making (2002) 0.83
The effect of weight loss on health, productivity, and medical expenditures among overweight employees. Med Care (2013) 0.82
Technical appendix: cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmology (2007) 0.80
Designing and implementing a comparative effectiveness study of two strategies for delivering high quality CHD prevention: methods and participant characteristics for the Heart to Health study. Contemp Clin Trials (2013) 0.80
Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Med Wkly (2012) 0.80
Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. Diabetes Care (2010) 0.80
Motivation for participating in a weight loss program and financial incentives: an analysis from a randomized trial. J Obes (2012) 0.79
Use of behavior change techniques in clean cooking interventions: a review of the evidence and scorecard of effectiveness. J Health Commun (2015) 0.77
Managing people at high risk for diabetes. Ann Intern Med (2006) 0.77
Prevalence of comorbidities and baseline characteristics of LAP-BAND AP® subjects in the Helping Evaluate Reduction in Obesity (HERO) study. PLoS One (2013) 0.75
Knowledge and perceptions among overweight and obese employees about lifestyle-related health benefit changes. N C Med J (2011) 0.75
Cost Minimization Analysis of Precut Cornea Grafts in Descemet Stripping Automated Endothelial Keratoplasty. Medicine (Baltimore) (2016) 0.75
Predicted patient demand for a new delivery system for glaucoma medicine. Medicine (Baltimore) (2017) 0.75
Inaugural conjoint analysis in health conference. Patient (2008) 0.75
Control of blood pressure and risk attenuation: a public health intervention in rural Bangladesh, Pakistan, and Sri Lanka: feasibility trial results. J Hypertens (2016) 0.75
A practical model for economic evaluation of tissue-engineered therapies. Wiley Interdiscip Rev Syst Biol Med (2015) 0.75
Recall of three heart disease risk factor diagnoses among low-income women. J Womens Health (Larchmt) (2009) 0.75